Hillevax

Hillevax Share Buybacks

Delisted

The Share Buybacks of Hillevax (HLVX) as of Nov 20, 2026 is 210.30 M USD.

Share Buybacks

210.30 MUSD

Last updated:

Share Buybacks of Hillevax is 2022 210.30 M USD. Share Buybacks of Hillevax was 2021 - USD. It decreases by % lower compared to the previous year.

The Hillevax Share Buybacks history

The Hillevax Share Buybacks history
YEARShare BuybacksYoY
210.30 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Hillevax Stock analysis

What does Hillevax do? HilleVax, Inc. develops and commercializes novel vaccines, focusing on HIL-214, a bivalent virus-like particle (VLP) vaccine candidate for norovirus-induced acute gastroenteritis. The vaccine combines VLPs for norovirus genotypes GI.1 and GII.4 with an aluminum hydroxide adjuvant to enhance immune response. HIL-214 targets moderate-to-severe cases of norovirus infection, which causes symptoms like diarrhea, vomiting, and dehydration. The company's primary revenue stream will come from the future commercialization of HIL-214 after regulatory approval, with potential sales to healthcare providers and public health programs. Hillevax is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Hillevax stock

Share Buybacks of Hillevax is 210.30 M USD in 2022.

On Eulerpool you can find the complete historical development of Share Buybacks Hillevax since 2006 – with annual values, charts, and detailed analysis.

Share buybacks represent the cash spent repurchasing the company's own shares. Buybacks reduce shares outstanding and can increase EPS.

Share Buybacks's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Share Buybacks's Hillevax historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Hillevax

All Key Metrics — Hillevax